Hospitalisation rate in individuals with schizophrenia treated with long acting injectable atypical antipsychotics in Latin America - the REALAI study

Página do item simplificado
dc.citation.volume27
dc.contributor.authorRodriguez, R.
dc.contributor.authorPalmeira, L.
dc.contributor.authorRamos, J.
dc.contributor.authorSoares, B. [UNIFESP]
dc.contributor.authorGuarniero, F.
dc.contributor.authorDiaz, J.
dc.coverageAmsterdam
dc.date.accessioned2020-08-04T13:39:59Z
dc.date.available2020-08-04T13:39:59Z
dc.date.issued2017
dc.description.affiliationCtr Invest Pro Salud Mental, Invest Clin, Mexico City, DF, Mexico
dc.description.affiliationPro Doctor Serv Med, Pesquisa Clin, Rio De Janeiro, Brazil
dc.description.affiliationClin Especialidades Neuropsiquiatr Tlatelolco, Ctr Invest Clin, Mexico City, DF, Mexico
dc.description.affiliationUniv Fed Sao Paulo, Psychiat, Sao Paulo, Brazil
dc.description.affiliationJanssen Cilag, Med Affairs, Lisbon, Portugal
dc.description.affiliationJanssen Cilag, Med Affairs, Bogota, Colombia
dc.description.affiliationUnifespUniv Fed Sao Paulo, Psychiat, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extentS960-S961
dc.identifierhttps://doi.org/10.1016/S0924-977X(17)31695-4
dc.identifier.citationEuropean Neuropsychopharmacology. Amsterdam, v. 27, p. S960-S961, 2017.
dc.identifier.doi10.1016/S0924-977X(17)31695-4
dc.identifier.issn0924-977X
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/57221
dc.identifier.wosWOS:000413847704028
dc.language.isoeng
dc.publisherElsevier Science Bv
dc.relation.ispartofEuropean Neuropsychopharmacology
dc.relation.ispartof30th Congress of the European-College-of-Neuropsychopharmacology (ECNP)
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.titleHospitalisation rate in individuals with schizophrenia treated with long acting injectable atypical antipsychotics in Latin America - the REALAI studyen
dc.typeinfo:eu-repo/semantics/conferenceObject
Arquivos
Coleções
EPM - Outras produções